Screening of Investigational Therapeutics to Treat, Modify or Prevent Epilepsy for the NINDS Epilepsy Therapy Screening Program (ETSP)

The National Institute of Neurological Disorders and Stroke (NINDS) is issuing a Sources‑Sought notice (Solicitation 75N98026R00040) to identify qualified firms capable of performing a 12‑month R&D effort—beginning 1 Jan 2027 with possible 12‑month extensions—to support the Epilepsy Therapy Screening Program (ETSP). The work will encompass three core performance areas: (1) implementation of an established workflow for drug‑resistant epilepsy, including acute and chronic seizure assays; (2) development of disease‑prevention and disease‑modification (antiepileptogenesis) models; and (3) pharmacokinetic studies to determine plasma and brain levels of investigational compounds in rats and mice. Ancillary studies may be required, such as assays for epilepsy co‑morbidities and supporting ADME/formulation work. The prime contractor must perform the majority of tasks in‑house and retain full responsibility for all deliverables, though limited domestic subcontracting is permissible. Respondents must submit a capability statement that addresses each performance area separately and includes total employee count, relevant professional qualifications, any GSA Schedule or GWAC contracts, and standard small‑business data (company name, UEI, address, point of contact, NAICS 541715, size standard, and SBA‑recognized status). No proprietary or confidential information may be included. Responses are to be emailed to Contracting Officer Rieka Plugge (rieka.plugge@nih.gov) no later than 06 Apr 2026 09:00 EST. This notice is for market research only; it does not constitute a solicitation, commitment, or award, and the Government will not incur costs for responses.

Notice ID

4705218c52e1476c8b7e22b16e97d670

Solicitation Number

75N98026R00040

NAICS Code

541715

Classification Code

AN12